Low-dose CT screening for patients at high risk of lung cancer can find smaller nodules than X-ray, but concern remains about potential harm from the test.
Low-dose CT screening for patients who are at increased risk of developing lung cancer can identify smaller nodules than can chest X-rays. But concern remains regarding potential harm from the screening, according to a study published online in JAMA.
Peter B. Bach, MD, of the Memorial Sloan-Kettering Cancer Center, New York, and colleagues assessed the results of several randomized controlled trials and cohort studies, finding that the National Lung Screening trial was the most informative, with 53,545 participants. The findings showed that the screening resulted in a 20 percent lower relative risk of death.
“In terms of potential harms of [low-dose CT] screening, across all trials and cohorts, approximately 20 percent of individuals in each round of screening had positive results requiring some degree of follow-up, while approximately 1 percent had lung cancer,” the study authors wrote.
“There was marked heterogeneity in this finding and in the frequency of follow-up investigations, biopsies, and percentage of surgical procedures performed in patients with benign lesions.”
The study authors concluded, however, that there is still uncertainty about the potential harms of screening and generalizability of the results.
Could Virtual Non-Contrast Images from Photon-Counting CT Reduce Radiation Dosing with CCTA?
March 28th 2024Emerging research on coronary artery calcium scoring for the assessment of coronary artery disease (CAD) suggests the use of virtual non-contrast images from photon-counting CT may lead to a nearly 20 percent reduction in radiation dosing.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears Mobile C-Arm Device that May Accelerate Fluoroscopic and 3D CT Imaging
March 21st 2024Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.